Dermatitis News

The FDA has approved Opzelura cream for the treatment of atopic dermatitis in non-immunocompromised patients, Incyte announced in a press release.

Health care workers with atopic dermatitis had greater irritation, dryness and other skin issues due to how frequently they washed their hands, according to a study published in Annals of Allergy, Asthma & Immunology.

A phase 3 trial of tapinarof cream for the treatment of atopic dermatitis has dosed its first patient, Dermavant Sciences announced in a press release.

Severe atopic dermatitis is associated with depression and internalizing behaviors in childhood and adolescence, according to a study.

A novel subtype of atopic eczema marked by increasing disease activity into adulthood was recently observed in a large population-based study.

Ligelizumab and omalizumab were found to be the most effective treatments for adolescent and adult patients with chronic spontaneous urticaria who had failed to respond to H1 antihistamines, according to a study.

Methotrexate and azathioprine yielded similar risk-benefit ratios as first-line therapy for children with severe atopic dermatitis, according to a study.

Pediatric patients with atopic dermatitis who were treated with Dupixent plus topical corticosteroids had significant reductions in itch and improved quality of life in a phase 3 trial, according to a press release.

Induction therapy with abrocitinib was associated with low flare rates in patients with moderate to severe atopic dermatitis, according to a study.

Oral abrocitinib, in combination with topical therapy, was effective and well tolerated in the treatment of moderate to severe atopic dermatitis in adolescents, according to phase 3 study results.